COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09/06/2025
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad [...]
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
09/06/2025
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE Nantes, France, 9 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), informe ses actionnaires et le marché de la mise à jour des modalités [...]
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
09/06/2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of [...]
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans
09/06/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'APPROBATION PAR L'EMA DE LA PROLONGATION DE LA DURÉE DE CONSERVATION DE MASIVET® À 4 ANS Paris, 9 juin 2025, 8h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui [...]
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
09/06/2025
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency ( [...]
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
08/06/2025
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of [...]
Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management
07/06/2025
Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers. New York, June 07, 2025 (GLOBE NEWSWIRE) -- Ro Weight Loss, a digital health service from [...]
Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™
06/06/2025
TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
06/06/2025
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) ( [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
06/06/2025
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Enovis to Participate in Upcoming Investor Conferences
06/06/2025
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following [...]
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that [...]
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
06/06/2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
06/06/2025
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will [...]
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
06/06/2025
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“ Rakovina ” or the “ Company ”), a biopharmaceutical company advancing innovative cancer therapies [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

Pages